Shaheen S. Sikandar

Shaheen S. Sikandar

Auto-generated profile, based on publicly available information

Shaheen S. Sikandar

University of California, Santa Cruz

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Science
Verified
Journal Article
Closed access
PDF file
GGGunsagar S. Gulati
Gunsagar S. Gulati
SSShaheen S. Sikandar
Shaheen S. Sikandar
DWDaniel J. Wesche
Daniel J. Wesche
AMAnoop Manjunath
Anoop Manjunath
ABAnjan Bharadwaj
Anjan Bharadwaj
ANAaron M. Newman
Aaron M. Newman
More diversity at the top: A detailed knowledge of cell differentiation hierarchies is important for understanding diverse biological processes such as organ development, tissue regeneration, and cancer. Single-cell RNA sequencing can help elucidate these hierarchies, but it requires reliable computational methods for predicting cell lineage trajectories. Gulati et al. developed CytoTRACE, a computational framework based on the simple observation that transcriptional diversity—the number of genes expressed in a cell—decreases during differentiation. CytoTRACE outperformed other methods in several test cases and was successfully applied to study cellular hierarchies in healthy and tumor tissue. Science , this issue p. 405

1 August 2020 in Cell Stem Cell
Verified
Journal Article
Closed access
MZMaider Zabala
Maider Zabala
NLNeethan A. Lobo
Neethan A. Lobo
JAJane Antony
Jane Antony
LHLuuk S. Heitink
Luuk S. Heitink
GGGunsagar S. Gulati
Gunsagar S. Gulati
MCMichael F. Clarke
Michael F. Clarke

11 November 2022 in Science Advances
Verified
Journal Article
Open access
SSShaheen S. Sikandar
Shaheen S. Sikandar
GGGunsagar S. Gulati
Gunsagar S. Gulati
JAJane Antony
Jane Antony
IFIsobel Fetter
Isobel Fetter
AKAngera H. Kuo
Angera H. Kuo
MCMichael F. Clarke
Michael F. Clarke
Metastasis is responsible for most breast cancer–related deaths; however, identifying the cellular determinants of metastasis has remained challenging. Here, we identified a minority population of immature THY1 + / VEGFA + tumor epithelial cells in human breast tumor biopsies that display angiogenic features and are marked by the expression of the oncogene, LMO2 . Higher abundance of LMO2 + basal cells correlated with tumor endothelial content and predicted poor distant recurrence–free survival in patients. Using MMTV-PyMT/Lmo2 CreERT2 mice, we demonstrated that Lmo2 lineage–traced cells integrate into the vasculature and have a higher propensity to metastasize. LMO2 knockdown in human breast tumors reduced lung metastasis by impairing intravasation, leading to a reduced frequency of circulating tumor cells. Mechanistically, we find that LMO2 binds to STAT3 and is required for STAT3 activation by tumor necrosis factor–α and interleukin-6. Collectively, our study identifies a population of metastasis-initiating cells with angiogenic features and establishes the LMO2-STAT3 signaling axis as a therapeutic target in breast cancer metastasis.

30 May 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
GGGunsagar Singh Gulati
Gunsagar Singh Gulati
SSShaheen S. Sikandar
Shaheen S. Sikandar
DWDaniel J. Wesche
Daniel J. Wesche
AMAnoop Manjunath
Anoop Manjunath
ABAnjan Bharadwaj
Anjan Bharadwaj
ANAaron M. Newman
Aaron M. Newman
Single-cell RNA-sequencing (scRNA-seq) is a powerful approach for reconstructing cellular differentiation trajectories. However, inferring both the state and direction of differentiation without prior knowledge has remained challenging. Here we describe a simple yet robust determinant of developmental potential—the number of detectably expressed genes per cell— and leverage this measure of transcriptional diversity to develop a new framework for predicting ordered differentiation states from scRNA-seq data. When evaluated on ~150,000 single-cell transcriptomes spanning 53 lineages and five species, our approach, called CytoTRACE, outperformed previous methods and ~19,000 molecular signatures for resolving experimentally-confirmed developmental trajectories. In addition, it enabled unbiased identification of tissue-resident stem cells, including cells with long-term regenerative potential. When used to analyze human breast tumors, we discovered candidate genes associated with less-differentiated luminal progenitor cells and validated GULP1 as a novel gene involved in tumorigenesis. Our study establishes a key RNA-based correlate of developmental potential and provides a new platform for robust delineation of cellular hierarchies ( https://cytotrace.stanford.edu ).

10 May 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
RHRobert W. Hsieh
Robert W. Hsieh
AKAngera H. Kuo
Angera H. Kuo
FSFerenc A Scheeren
Ferenc A Scheeren
MZMark A. Zarnegar
Mark A. Zarnegar
SSShaheen S. Sikandar
Shaheen S. Sikandar
MCMichael F. Clarke
Michael F. Clarke
Triple-negative breast cancer (TNBC) is a poor prognosis disease with no clinically approved targeted therapies. Here, using in vitro and in vivo RNA interference (RNAi) screens in TNBC patient-derived xenografts (PDX), we identify cyclin dependent kinase 19 (CDK19) as a potential therapeutic target. Using in vitro and in vivo TNBC PDX models, we validated the inhibitory effect of CDK19 knockdown on tumor initiation, proliferation and metastases. Despite this, CDK19 knockdown did not affect the growth of non-transformed mammary epithelial cells. Using CD10 and EpCAM as novel tumor initiating cell (TIC) markers, we found the EpCAM med/high /CD10 −/low TIC sub-population to be enriched in CDK19 and a putative cellular target of CDK19 inhibition. Comparative gene expression analysis of CDK19 and CDK8 knockdowns revealed that CDK19 regulates a number of cancer-relevant pathways, uniquely through its own action and others in common with CDK8. Furthermore, although it is known that CDK19 can act at enhancers, our CHIP-Seq studies showed that CDK19 can also epigenetically modulate specific H3K27Ac enhancer signals which correlate with gene expression changes. Finally, to assess the potential therapeutic utility of CDK19, we showed that both CDK19 knockdown and chemical inhibition of CDK19 kinase activity impaired the growth of pre-established PDX tumors in vivo . Current strategies inhibiting transcriptional co-factors and targeting TICs have been limited by toxicity to normal cells. Because of CDK19’s limited tissue distribution and the viability of CDK19 knockout mice, CDK19 represents a promising therapeutic target for TNBC.

5 December 2025 in Cancer Heterogeneity and Plasticity
Verified
Journal Article
Open access
BDBiswajit Das
Biswajit Das
CWCharles W. Winterbottom
Charles W. Winterbottom
SSShaheen S. Sikandar
Shaheen S. Sikandar
Breast cancer (BC) is the most common type of cancer among females, and the number of deaths due to BC has increased over the past few decades. BC is primarily categorized based on the receptor status of BC cells as hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+), and triple-negative BC (TNBC). These subtypes differ significantly in their treatment strategies, prognosis, immunogenic nature, and response to immunotherapy. TNBC is the most aggressive with a poor prognosis, but a subset of TNBCs that express programmed cell death ligand 1, have shown promising responses to immune checkpoint inhibitors. Across BC subtypes, distinct immune cell subsets remain active in the tumor immune microenvironment (TIME) that either inhibit or promote the growth of cancer. In isolation, it is challenging for cancer cells to thrive in presence of the body’s immune system, however with the aid of other cells in the TIME, they can work together to evade immune detection by suppressing antigen presentation, modulating immune recognition markers, and recruiting immune-suppressive cells. In this review, we provide an overview of the BC immune evasion mechanisms and discuss aspects of immune evasion in relation to tumor heterogeneity and cellular plasticity. We also highlight successful clinical trials targeting immune-evasion markers and discuss the challenges and potential future directions for solving these problems.